Literature DB >> 22166248

Urinary prostaglandin E2 metabolite and risk for colorectal adenoma.

Martha J Shrubsole1, Qiuyin Cai, Wanqing Wen, Ginger Milne, Walter E Smalley, Zhi Chen, Reid M Ness, Wei Zheng.   

Abstract

COX-2 is upregulated in most colorectal cancers. Most of the COX-2 tumor-inducing effects are believed to be mediated through overproduction of prostaglandin E(2) (PGE(2)), which can be measured using a urinary metabolite of PGE(2), PGE-M. Urinary PGE-M was assessed in a case-control study of colorectal adenoma. Included in the analysis were 224 cases with at least one advanced adenoma, 152 cases with multiple small tubular adenomas, 300 cases with only a single small tubular adenoma, and 364 polyp-free controls. There were no statistical differences in PGE-M levels between controls and cases with a single small tubular adenoma. However, cases with either an advanced adenoma or multiple small tubular adenomas had more than 25% higher levels of PGE-M than controls. Participants with the highest quartile level of PGE-M were approximately 2.5-fold more likely to have advanced or multiple small tubular adenoma in comparison with those with the lowest level of PGE-M [OR = 2.53; 95% confidence interval (CI), 1.54-4.14; P(trend) < 0.001]. The association was strongest among women. PGE-M level was associated with increased risk for multiple or advanced adenoma but not single small adenoma. Our study suggests that PGE-M may be a useful risk marker for assessing the risk of harboring clinically more important versus less important colorectal neoplasia. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22166248      PMCID: PMC3273609          DOI: 10.1158/1940-6207.CAPR-11-0426

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  37 in total

1.  Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia.

Authors:  J Chad Johnson; Carl R Schmidt; Martha J Shrubsole; D Dean Billheimer; Prashant R Joshi; Jason D Morrow; Martin J Heslin; M Kay Washington; Reid M Ness; Wei Zheng; David A Schwartz; Robert J Coffey; R Daniel Beauchamp; Nipun B Merchant
Journal:  Clin Gastroenterol Hepatol       Date:  2006-09-25       Impact factor: 11.382

2.  Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk.

Authors:  Qiuyin Cai; Yu-Tang Gao; Wong-Ho Chow; Xiao-Ou Shu; Gong Yang; Bu-Tian Ji; Wanqing Wen; Nathaniel Rothman; Hong-Lan Li; Jason D Morrow; Wei Zheng
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

3.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

Authors:  Bernard F Cole; Richard F Logan; Susan Halabi; Robert Benamouzig; Robert S Sandler; Matthew J Grainge; Stanislas Chaussade; John A Baron
Journal:  J Natl Cancer Inst       Date:  2009-02-10       Impact factor: 13.506

Review 4.  The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.

Authors:  Alexander Greenhough; Helena J M Smartt; Amy E Moore; Heather R Roberts; Ann C Williams; Christos Paraskeva; Abderrahmane Kaidi
Journal:  Carcinogenesis       Date:  2009-01-09       Impact factor: 4.944

5.  Aspirin use and survival after diagnosis of colorectal cancer.

Authors:  Andrew T Chan; Shuji Ogino; Charles S Fuchs
Journal:  JAMA       Date:  2009-08-12       Impact factor: 56.272

6.  Alcohol drinking, cigarette smoking, and risk of colorectal adenomatous and hyperplastic polyps.

Authors:  Martha J Shrubsole; Huiyun Wu; Reid M Ness; Yu Shyr; Walter E Smalley; Wei Zheng
Journal:  Am J Epidemiol       Date:  2008-02-27       Impact factor: 4.897

7.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.

Authors:  Andrew T Chan; Shuji Ogino; Charles S Fuchs
Journal:  N Engl J Med       Date:  2007-05-24       Impact factor: 91.245

8.  Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.

Authors:  Monica M Bertagnolli; Craig J Eagle; Ann G Zauber; Mark Redston; Aurora Breazna; Kyungmann Kim; Jie Tang; Rebecca B Rosenstein; Asad Umar; Donya Bagheri; Neal T Collins; John Burn; Daniel C Chung; Thomas Dewar; T Raymond Foley; Neville Hoffman; Finlay Macrae; Ronald E Pruitt; John R Saltzman; Bruce Salzberg; Thomas Sylwestrowicz; Ernest T Hawk
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-31

9.  Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.

Authors:  Anna J Duffield-Lillico; Jay O Boyle; Xi Kathy Zhou; Aradhana Ghosh; Geera S Butala; Kotha Subbaramaiah; Robert A Newman; Jason D Morrow; Ginger L Milne; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-31

Review 10.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.

Authors:  Jack Cuzick; Florian Otto; John A Baron; Powel H Brown; John Burn; Peter Greenwald; Janusz Jankowski; Carlo La Vecchia; Frank Meyskens; Hans Jörg Senn; Michael Thun
Journal:  Lancet Oncol       Date:  2009-05       Impact factor: 41.316

View more
  30 in total

Review 1.  Role of prostanoids in gastrointestinal cancer.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

2.  PUFA levels in erythrocyte membrane phospholipids are differentially associated with colorectal adenoma risk.

Authors:  Samara B Rifkin; Martha J Shrubsole; Qiuyin Cai; Walter E Smalley; Reid M Ness; Larry L Swift; Wei Zheng; Harvey J Murff
Journal:  Br J Nutr       Date:  2017-06-29       Impact factor: 3.718

3.  Role of inflammation and inflammatory mediators in colorectal cancer.

Authors:  Raymond N Dubois
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

4.  PPARδ and PGE2 signaling pathways communicate and connect inflammation to colorectal cancer.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  Inflamm Cell Signal       Date:  2014-10-19

Review 5.  Early detection of colorectal cancer: from conventional methods to novel biomarkers.

Authors:  Nasimeh Vatandoost; Jahanafrooz Ghanbari; Mahboobeh Mojaver; Amir Avan; Majid Ghayour-Mobarhan; Reza Nedaeinia; Rasoul Salehi
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-17       Impact factor: 4.553

6.  Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk.

Authors:  Yong Cui; Xiao-Ou Shu; Hong-Lan Li; Gong Yang; Wanqing Wen; Yu-Tang Gao; Qiuyin Cai; Nathaniel Rothman; Hui-Yong Yin; Qing Lan; Yong-Bing Xiang; Wei Zheng
Journal:  Int J Cancer       Date:  2017-08-29       Impact factor: 7.396

7.  Effects of fish oil supplementation on eicosanoid production in patients at higher risk for colorectal cancer.

Authors:  Maya N White; Martha J Shrubsole; Qiuyin Cai; Timothy Su; Jennings Hardee; John-Anthony Coppola; Sunny S Cai; Stephanie M Martin; Sandra Motley; Larry L Swift; Ginger L Milne; Wei Zheng; Qi Dai; Harvey J Murff
Journal:  Eur J Cancer Prev       Date:  2019-05       Impact factor: 2.497

8.  Plasma lipid levels and colorectal adenoma risk.

Authors:  John-Anthony Coppola; Martha J Shrubsole; Qiuyin Cai; Walter E Smalley; Qi Dai; Reid M Ness; Sergio Fazio; Wei Zheng; Harvey J Murff
Journal:  Cancer Causes Control       Date:  2015-03-12       Impact factor: 2.506

9.  Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk.

Authors:  James R Davenport; Qiuyin Cai; Reid M Ness; Ginger Milne; Zhiguo Zhao; Walter E Smalley; Wei Zheng; Martha J Shrubsole
Journal:  Mol Carcinog       Date:  2015-08-31       Impact factor: 4.784

10.  Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS).

Authors:  Veronika Fedirko; Patrick T Bradshaw; Jane C Figueiredo; Robert S Sandler; Elizabeth L Barry; Dennis J Ahnen; Ginger L Milne; Robert S Bresalier; John A Baron
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.